Molecular and Cellular Biochemistry

, Volume 352, Issue 1–2, pp 301–307

Effect of acute and chronic zofenopril administration on cardiac gene expression

  • Vittoria Carnicelli
  • Sabina Frascarelli
  • Riccardo Zucchi
Article

Abstract

We investigated whether acute and chronic administration of zofenopril, an angiotensin converting enzyme inhibitor, may modulate the expression of genes which are involved in the pathophysiology of myocardial ischemia and heart failure. We used an acute and a chronic model. In the former isolated rat hearts were perfused for 120 min in the presence or in the absence of 10 μM zofenoprilat, the active metabolite of zofenopril. In the chronic model one group of rats was treated with zofenopril (15.2 mg/Kg die per os) for 15 days, while control rats were treated with the same diet, except that zofenopril was omitted. Total RNA was extracted from hearts, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to evaluate the expression of α myosin heavy chain, superoxide dismutase, heat shock protein 70 (HSP70), nitric oxide synthase 2 and 3 (NOS2, NOS3), heme oxygenase 1, atrial natriuretic peptide (ANP), muscle phosphofructokinase. Acute or chronic zofenopril administration did not produce any change in hemodynamic variables. qRT-PCR experiments showed that in the acute model ANP expression was slightly although not significantly increased. In the chronic model, significant changes in gene expression were detected: in particular, HSP70 was upregulated (1.06 ± 0.38 vs. 0.72 ± 0.20 arbitrary units, P = 0.025), while NOS3 was downregulated (0.66 ± 0.06 vs. 0.83 ± 0.18 arbitrary units, P = 0.007). In the chronic model, liver samples were also assayed, but no significant change in the expression of any gene was detected. We conclude that zofenopril can produce heart-specific effects on gene expression. Persistent changes were detected with regard to specific heat shock protein and nitric oxide synthase subtypes. This action might contribute to the therapeutical response, and particularly to the increased resistance to ischemia.

Keywords

ACEI Zofenopril Cardiac remodeling Ischemia HSP70 NOS3 ANP 

References

  1. 1.
    Maggioni AP (2006) Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 20:295–308PubMedCrossRefGoogle Scholar
  2. 2.
    Prisant LM (2008) Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 121:S8–S15PubMedCrossRefGoogle Scholar
  3. 3.
    Pfeffer MA, Frohlich ED (2006) Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am J Physiol Heart Circ Physiol 291:H2021–H2025PubMedCrossRefGoogle Scholar
  4. 4.
    Sanoudou D, Vafiadaki E, Arvanitis DA, Kranias E, Kontrogianni-Konstantopoulos A (2005) Array lessons from the heart: focus on genome and transcriptome of cardiomyopathies. Physiol Genomics 21:131–143PubMedCrossRefGoogle Scholar
  5. 5.
    McKinsey TA, Olson EN (2005) Towards transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115:538–546PubMedGoogle Scholar
  6. 6.
    Depre C, Tomlinson JE, Kudej RK, Gaussin V, Thompson E, Kim SJ, Vatner DE, Topper JN, Vatner SF (2001) Gene program for cell survival induced by transient ischemia in conscious pig. Proc Natl Acad Sci USA 98:9336–9341PubMedCrossRefGoogle Scholar
  7. 7.
    Da Silva E, Lucchinetti E, Pasch T, Schaub MC, Zaugg M (2004) Ischemic but not pharmacological preconditioning elicits a gene expression profile similar to unprotected myocardium. Physiol Genomics 20:117–130PubMedCrossRefGoogle Scholar
  8. 8.
    Das DK, Maulik N (2006) Cardiac genomic response following preconditioning stimulus. Cardiovasc Res 70:254–263PubMedCrossRefGoogle Scholar
  9. 9.
    Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y (2008) Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci 108:487–494PubMedCrossRefGoogle Scholar
  10. 10.
    Jin H, Yang R, Awad TA, Wang F, Li W, Williams SP, Ogasawara A, Shimada B, Williams PM, de Feo G, Paoni NF (2001) Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation 103:736–742PubMedGoogle Scholar
  11. 11.
    De Gennaro Colonna V, Rossoni G, Rigamonti AE, Bonomo S, Manfredi B, Berti F, Muller E (2002) Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 450:61–66PubMedCrossRefGoogle Scholar
  12. 12.
    Frascarelli S, Carnicelli V, Ghelardoni S, Chiellini G, Ronca F, Zucchi R (2009) Effects of zofenopril on cardiac sarcoplasmic reticulum calcium handling. J Cardiovasc Pharmacol 54:456–463PubMedCrossRefGoogle Scholar
  13. 13.
    Liu X, Engelman RM, Ronson JA, Cordis GA, Das DK (1992) Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotesin converting enzyme inhibitors. Cardiovasc Drugs Ther 6:437–443PubMedCrossRefGoogle Scholar
  14. 14.
    Tio AR, de Langen CD, de Graeff PA, van Gilst WH, Bel KJ, Wolters KG, Mook PH, van Wijngaarden J, Wesseling H (1990) The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drug Ther 4:695–704CrossRefGoogle Scholar
  15. 15.
    Przyklenk K, Kloner KA (1991) Angiotensin converting enzyme inhibitors improved contractile function of stunned myocardium by different mechanisms of action. Am Heart J 121:1319–1330PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrari R, Cargnoni A, Curello S, Ceconi C, Boraso A, Visioli O (1992) Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol 20:694–704PubMedGoogle Scholar
  17. 17.
    Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R (2004) Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 43:294–299PubMedCrossRefGoogle Scholar
  18. 18.
    Ambrosioni E, Borghi C, Magnani B (1995) The effect of angiotensine-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. New Engl J Med 332:80–85PubMedCrossRefGoogle Scholar
  19. 19.
    Borghi C, Ambrosioni E (2003) Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 145:80–87PubMedCrossRefGoogle Scholar
  20. 20.
    Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002–2007CrossRefGoogle Scholar
  21. 21.
    Tupling AR, Bombardier E, Vigna C, Quadrilatero J, Fu M (2008) Interaction between Hsp70 and the SR Ca2+ pump: a potential mechanism for cytoprotection in heart and skeletal muscle. Appl Physiol Nutr Metab 33(5):1023–1032PubMedCrossRefGoogle Scholar
  22. 22.
    Darra E, Rungatscher A, Carcereri de Prati A, Podesser BK, Faggian G, Scarabelli T, Mazzucco A, Hallström S, Suzuki H (2010) Dual modulation of nitric oxide production in the heart during ischaemia/reperfusion injury and inflammation. Thromb Haemost 104(2):200–206PubMedCrossRefGoogle Scholar
  23. 23.
    Erdös EG, Tan F, Skidgel RA (2010) Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 55:214–220PubMedCrossRefGoogle Scholar
  24. 24.
    Balligand JL, Feron O, Dessy C (2009) eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev 89:481–534PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang MX, Ou H, Shen YH, Wang J, Wang J, Coselli J, Wang XL (2005) Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 102:16967–16972PubMedCrossRefGoogle Scholar
  26. 26.
    Kobayashi N, Hara K, Watanabe S, Higashi T, Matsuoka H (2000) Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. Am J Hypertens 13:199–207PubMedCrossRefGoogle Scholar
  27. 27.
    Linz W, Jessen T, Becker RH, Schölkens BA, Wiemer G (1997) Long -term ACE inhibition doubles lifespan of hypertensive rats. Circulation 96(9):3164–3172PubMedGoogle Scholar
  28. 28.
    Dietz JR (2005) Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 68:8–17PubMedCrossRefGoogle Scholar
  29. 29.
    Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318–328PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Vittoria Carnicelli
    • 1
  • Sabina Frascarelli
    • 1
  • Riccardo Zucchi
    • 1
    • 2
  1. 1.Dipartimento di Scienze dell’Uomo e dell’AmbienteUnità di Biochimica Medica, University of PisaPisaItaly
  2. 2.Dipartimento di Scienze dell’Uomo e dell’AmbienteUnità di Biochimica MedicaPisaItaly

Personalised recommendations